NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it intends to sell its HemoCue point-of-care diagnostics business and will report results associated with that business, as well as the OralDNA business that it sold last month, as discontinued operations in its fourth-quarter financials. Quest said that it expects to take a charge of $89.5 million, or $.56 per share, related to the discontinued operations for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.